ClinicalTrials.Veeva

Menu
E

Evolution Research Group | Woodland International Research Group

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SEP-363856
KarXT
Rapastinel
Cariprazine
Lurasidone
Brexpiprazole
Rimegepant
Aripiprazole
Acetaminophen
Bupivacaine Hydrochloride

Parent organization

This site is a part of Evolution Research Group

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 104 total trials

A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE. Master Protocol HTX-011-401.

This is a Phase 4, randomized, blinded, active-controlled, multicohort study to evaluate HTX-011 compared with bupivacaine HCl in subjects undergoing...

Active, not recruiting
Analgesia
Drug: HTX-011
Drug: Acetaminophen

This is a Phase 3, randomized, double blind, multicenter study to evaluate the analgesic efficacy and safety of a single intra-articular dose of F14...

Active, not recruiting
Post Operative Pain
Drug: 0.25 % Bupivacaine HCl
Drug: Methocarbamol

This clinical trial is a Phase 2/3 study that will evaluate the efficacy and safety of etavopivat and test how well etavopivat works compared to plac...

Enrolling
Sickle Cell Disease
Drug: Placebo Tablets
Drug: Etavopivat Tablets High dose

This is a Phase 3, 6-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with schizophrenia with an inadequ...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules
Drug: Placebo

This is a Phase 3, multicenter, 52-week, outpatient, open-label extension (OLE) study to evaluate the long-term safety and tolerability of adjunctive...

Enrolling
Schizophrenia
Drug: Xanomeline and Trospium Chloride Capsules

The ENCALM trial is designed to evaluate the efficacy and safety of ENX-102 in patients diagnosed with generalized anxiety disorder (GAD)

Enrolling
Generalized Anxiety Disorder
Drug: Placebo
Drug: ENX-102

Open label extension, long-term multicenter study of safety and efficacy of SPN-812 in pediatric ADHD patients

Active, not recruiting
Attention-Deficit/Hyperactivity Disorder
Drug: SPN-812

Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and so...

Active, not recruiting
Episodic Migraine
Drug: Placebo
Drug: BOTOX

Trial sponsors

Otsuka logo
Indivior logo
Sumitomo Pharma logo
Karuna Therapeutics logo
Allergan logo
AbbVie logo
Forest Laboratories logo
Pfizer logo
Merck Sharp & Dohme (MSD) logo
Allergan logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems